Clinical Trial

Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-06-13; most recent amendment 2026-02-18.
Status change: Recruiting → Active, Not Recruiting 2026-02-18
Status change: Not Yet Recruiting → Recruiting 2024-08-21
Trial Details
NCT Number NCT06460844
Lead Sponsor Ray Therapeutics, Inc.
Conditions Retinitis Pigmentosa, Choroideremia
Enrollment 10 participants
Start Date 2024-08-27
Primary Completion 2030-10 (estimated)
Study Completion 2030-10 (estimated)
Updated on ClinicalTrials.gov 2026-02-20